FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018854441> ?p ?o ?g. }

• W2018854441 endingPage "S20" @default.
• W2018854441 startingPage "S20" @default.
• W2018854441 abstract "Few data exist on the comparative safety and immunogenicity of different COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of booster vaccines, we investigated the reactogenicity and immunogenicity of seven different COVID-19 vaccines as a third dose after two doses of ChAdOx1 nCov-19 (Oxford–AstraZeneca; hereafter referred to as ChAd) or BNT162b2 (Pfizer–BioNtech, hearafter referred to as BNT).COV-BOOST is a multicentre, randomised, controlled, phase 2 trial of third dose booster vaccination against COVID-19. Participants were aged older than 30 years, and were at least 70 days post two doses of ChAd or at least 84 days post two doses of BNT primary COVID-19 immunisation course, with no history of laboratory-confirmed SARS-CoV-2 infection. 18 sites were split into three groups (A, B, and C). Within each site group (A, B, or C), participants were randomly assigned to an experimental vaccine or control. Group A received NVX-CoV2373 (Novavax; hereafter referred to as NVX), a half dose of NVX, ChAd, or quadrivalent meningococcal conjugate vaccine (MenACWY)control (1:1:1:1). Group B received BNT, VLA2001 (Valneva; hereafter referred to as VLA), a half dose of VLA, Ad26.COV2.S (Janssen; hereafter referred to as Ad26) or MenACWY (1:1:1:1:1). Group C received mRNA1273 (Moderna; hereafter referred to as m1273), CVnCov (CureVac; hereafter referred to as CVn), a half dose of BNT, or MenACWY (1:1:1:1). Participants and all investigatory staff were blinded to treatment allocation. Coprimary outcomes were safety and reactogenicity and immunogenicity of anti-spike IgG measured by ELISA. The primary analysis for immunogenicity was on a modified intention-to-treat basis; safety and reactogenicity were assessed in the intention-to-treat population. Secondary outcomes included assessment of viral neutralisation and cellular responses. This trial is registered with ISRCTN, number 73765130.Between June 1 and June 30, 2021, 3498 people were screened. 2878 participants met eligibility criteria and received COVID-19 vaccine or control. The median ages of ChAd/ChAd-primed participants were 53 years (IQR 44–61) in the younger age group and 76 years (73–78) in the older age group. In the BNT/BNT-primed participants, the median ages were 51 years (41–59) in the younger age group and 78 years (75–82) in the older age group. In the ChAd/ChAD-primed group, 676 (46·7%) participants were female and 1380 (95·4%) were White, and in the BNT/BNT-primed group 770 (53·6%) participants were female and 1321 (91·9%) were White. Three vaccines showed overall increased reactogenicity: m1273 after ChAd/ChAd or BNT/BNT; and ChAd and Ad26 after BNT/BNT. For ChAd/ChAd-primed individuals, spike IgG geometric mean ratios (GMRs) between study vaccines and controls ranged from 1·8 (99% CI 1·5–2·3) in the half VLA group to 32·3 (24·8–42·0) in the m1273 group. GMRs for wild-type cellular responses compared with controls ranged from 1·1 (95% CI 0·7–1·6) for ChAd to 3·6 (2·4–5·5) for m1273. For BNT/BNT-primed individuals, spike IgG GMRs ranged from 1·3 (99% CI 1·0–1·5) in the half VLA group to 11·5 (9·4–14·1) in the m1273 group. GMRs for wild-type cellular responses compared with controls ranged from 1·0 (95% CI 0·7–1·6) for half VLA to 4·7 (3·1–7·1) for m1273. The results were similar between those aged 30–69 years and those aged 70 years and older. Fatigue and pain were the most common solicited local and systemic adverse events, experienced more in people aged 30–69 years than those aged 70 years or older. Serious adverse events were uncommon, similar in active vaccine and control groups. In total, there were 24 serious adverse events: five in the control group (two in control group A, three in control group B, and zero in control group C), two in Ad26, five in VLA, one in VLA-half, one in BNT, two in BNT-half, two in ChAd, one in CVn, two in NVX, two in NVX-half, and one in m1273.All study vaccines boosted antibody and neutralising responses after ChAd/ChAd initial course and all except one after BNT/BNT, with no safety concerns. Substantial differences in humoral and cellular responses, and vaccine availability will influence policy choices for booster vaccination.UK Vaccine Taskforce and National Institute for Health Research." @default.
• W2018854441 created "2016-06-24" @default.
• W2018854441 creator A5009426444 @default.
• W2018854441 creator A5016801657 @default.
• W2018854441 creator A5023109735 @default.
• W2018854441 creator A5025095574 @default.
• W2018854441 creator A5044226910 @default.
• W2018854441 creator A5052898248 @default.
• W2018854441 creator A5053107427 @default.
• W2018854441 creator A5053792034 @default.
• W2018854441 creator A5059512503 @default.
• W2018854441 creator A5067282800 @default.
• W2018854441 creator A5070150511 @default.
• W2018854441 creator A5077862296 @default.
• W2018854441 creator A5084166117 @default.
• W2018854441 date "2009-01-01" @default.
• W2018854441 modified "2023-10-18" @default.
• W2018854441 title "P.015 Prevalence and risk factors of betapapillomavirus infections in immunocompetent individuals without skin cancer" @default.
• W2018854441 doi "https://doi.org/10.1016/s1386-6532(08)70078-7" @default.
• W2018854441 hasPublicationYear "2009" @default.
• W2018854441 type Work @default.
• W2018854441 sameAs 2018854441 @default.
• W2018854441 citedByCount "0" @default.
• W2018854441 crossrefType "journal-article" @default.
• W2018854441 hasAuthorship W2018854441A5009426444 @default.
• W2018854441 hasAuthorship W2018854441A5016801657 @default.
• W2018854441 hasAuthorship W2018854441A5023109735 @default.
• W2018854441 hasAuthorship W2018854441A5025095574 @default.
• W2018854441 hasAuthorship W2018854441A5044226910 @default.
• W2018854441 hasAuthorship W2018854441A5052898248 @default.
• W2018854441 hasAuthorship W2018854441A5053107427 @default.
• W2018854441 hasAuthorship W2018854441A5053792034 @default.
• W2018854441 hasAuthorship W2018854441A5059512503 @default.
• W2018854441 hasAuthorship W2018854441A5067282800 @default.
• W2018854441 hasAuthorship W2018854441A5070150511 @default.
• W2018854441 hasAuthorship W2018854441A5077862296 @default.
• W2018854441 hasAuthorship W2018854441A5084166117 @default.
• W2018854441 hasConcept C121332964 @default.
• W2018854441 hasConcept C12590561 @default.
• W2018854441 hasConcept C126322002 @default.
• W2018854441 hasConcept C1276947 @default.
• W2018854441 hasConcept C147483822 @default.
• W2018854441 hasConcept C168563851 @default.
• W2018854441 hasConcept C187212893 @default.
• W2018854441 hasConcept C203014093 @default.
• W2018854441 hasConcept C203165030 @default.
• W2018854441 hasConcept C22070199 @default.
• W2018854441 hasConcept C2777704310 @default.
• W2018854441 hasConcept C2780801004 @default.
• W2018854441 hasConcept C2780868878 @default.
• W2018854441 hasConcept C71924100 @default.
• W2018854441 hasConceptScore W2018854441C121332964 @default.
• W2018854441 hasConceptScore W2018854441C12590561 @default.
• W2018854441 hasConceptScore W2018854441C126322002 @default.
• W2018854441 hasConceptScore W2018854441C1276947 @default.
• W2018854441 hasConceptScore W2018854441C147483822 @default.
• W2018854441 hasConceptScore W2018854441C168563851 @default.
• W2018854441 hasConceptScore W2018854441C187212893 @default.
• W2018854441 hasConceptScore W2018854441C203014093 @default.
• W2018854441 hasConceptScore W2018854441C203165030 @default.
• W2018854441 hasConceptScore W2018854441C22070199 @default.
• W2018854441 hasConceptScore W2018854441C2777704310 @default.
• W2018854441 hasConceptScore W2018854441C2780801004 @default.
• W2018854441 hasConceptScore W2018854441C2780868878 @default.
• W2018854441 hasConceptScore W2018854441C71924100 @default.
• W2018854441 hasLocation W20188544411 @default.
• W2018854441 hasOpenAccess W2018854441 @default.
• W2018854441 hasPrimaryLocation W20188544411 @default.
• W2018854441 hasRelatedWork W2022744425 @default.
• W2018854441 hasRelatedWork W2040482600 @default.
• W2018854441 hasRelatedWork W4200439415 @default.
• W2018854441 hasRelatedWork W4225421388 @default.
• W2018854441 hasRelatedWork W4283647070 @default.
• W2018854441 hasRelatedWork W4283694088 @default.
• W2018854441 hasRelatedWork W4293075968 @default.
• W2018854441 hasRelatedWork W4311960398 @default.
• W2018854441 hasRelatedWork W4318542652 @default.
• W2018854441 hasRelatedWork W4323305873 @default.
• W2018854441 hasVolume "44" @default.
• W2018854441 isParatext "false" @default.
• W2018854441 isRetracted "false" @default.
• W2018854441 magId "2018854441" @default.
• W2018854441 workType "article" @default.